Answers are grounded in this paper and cite their sources.
Management of the clinically negative neck (cN0) in patients with head and neck squamous cell carcinoma (HNSCC) has been a controversial issue for decades. The main argument for elective treatment is that if the neck is not treated, occult metastases will progress into clinically manifest metastases, and that delayed treatment of these lymph node metastases is associated with poorer oncological outcome. The primary counterargument is that the majority of patients are subjected to unnecessary treatment and its associated morbidity. Elective treatment of the neck is generally indicated when the likelihood of occult, clinically undetectable lymph node metastases is high and when the patient will be unavailable for regular followup. The clinically negative neck is also treated surgically when the neck needs to be entered for resection of the primary tumor or reconstruction of the surgical defect. When there is lower likelihood of occult lymph node metastases, the choice is between elective treatment and watchful waiting. This question arises in patients who have smaller (T1 and T2) oral squamous cell carcinoma (OSCC), because in these tumors the neck is usually not entered surgically for resection or reconstruction. The comparison of these approaches (ie, elective treatment or observation) depends on many factors, including the risk of occult lymph node metastases. Therefore, in studies investigating outcome in patients with a cN0 neck, a clear definition of “clinically N0” is mandatory. Is a diagnosis made after palpation of the neck only or after extensive diagnostic workup? In the last decade, many advances in diagnostic modalities to detect occult lymph node metastases in HNSCC have been made. It is likely that in patients with a higher incidence of occult lymph node metastases, the calculated risk of a poorer survival after observation of the neck as compared with elective neck dissection (END) will be higher. Improved detection of occult metastasis may lower the risk of delayed clinical lymph node metastases during followup and may favor observation. In a large, singlecenter, randomized controlled trial, D’Cruz et al found that END results in higher rates of overall and diseasefree survival than observation with therapeutic neck dissection in patients in whom lymph node metastases are detected during followup. Unfortunately, in this study, the cN0 was not clearly defined. Neck metastasis became apparent in 45% of patients in the observation group, suggesting a less accurate diagnostic workup compared with typical practice. In most studies, the incidence of occult lymph node metastasis in early stage OSCC is 20% to 30%. It can be anticipated that if the detection of occult metastases improves, the role of END evolves. Both [F]fludeoxyglucose (FDG) positron emission tomography– computed tomography (PETCT) and sentinel lymph node biopsy (SLNB) have been shown to detect occult lymph node metastases with high accuracy. For early stage OSCC, SLNB is a reliable diagnostic alternative for END. In a recent retrospective study of 8328 patients with cT12cN0 OCSCC who underwent staging of the neck by SLNB (n = 240 [2.9%]) or END from the US National Cancer Database, the overall survival was similar (after adjustment), but SLNB was associated with reduced perioperative morbidity, length of hospital stay, and perioperative 30day mortality. A recent retrospective, multicenter study that included 390 patients staged by END and 488 patients staged by SLNB found comparable overall sensitivity (84% vs 81%) and negative predictive value (NPV) (both 93%), also when stratified for pathological primary tumor (T) stages. In the French SentiMER trial, the only randomized controlled clinical trial, 307 patients with cT12N0 were randomly assigned between END and SNLB. Recurrencefree, locoregionalfree,
No takes yet. Share an insight, caveat, or question.
Bree et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: